Incremental Value of Systematic Biopsy in Patients with Prostate Imaging Reporting and Data System 5 Lesions Undergoing MRI–Ultrasound Fusion Biopsy: A Single-Operator Study in a Secondary-Care Setting

Background/Objectives: This study aimed to evaluate the incremental value of systematic biopsy (SB) in addition to targeted biopsy (TB) and its impact on Grade Group (GG) reclassification in patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions. Methods: We retrospectively reviewed data from 32 patients with PI-RADS 5-only lesions who underwent magnetic resonance imaging–ultrasound fusion transrectal biopsy by a single operator. Based on the patient-level maximum GG, we evaluated the detection of any prostate cancer (GG ≥ 1), clinically significant prostate cancer (GG ≥ 2), and high-grade prostate cancer (GG ≥ 3). An exploratory subgroup analysis was performed according to prostate-specific antigen density (PSAD; <0.15 vs. ≥0.15 ng/mL/mL). Results: Any prostate cancer was detected in 24 patients (75.0%) using TB, with no incremental detection using SB (0.0%; 95% confidence interval [CI], 0.0–10.9). Clinically significant prostate cancer was detected in 21 patients (65.6%) using TB, with incremental detection using SB in one patient (3.1%; 95% CI, 0.1–16.2). High-grade prostate cancer was detected in 17 patients (53.1%) using TB, with incremental detection using SB in one patient (3.1%; 95% CI, 0.1–16.2). The maximum GG was higher in three patients (9.4%) when TB and SB were combined. Among the 20 patients with PSAD ≥ 0.15 ng/mL/mL, no incremental detection of clinically significant prostate cancer or high-grade prostate cancer was observed using SB (0.0%; 95% CI, 0.0–16.8). Conclusions: In this cohort of patients with PI-RADS 5 lesions, the incremental value of SB for cancer detection was limited, although the upper limit of the 95% CI for incremental detection of clinically significant prostate cancer was 16.2%. Nevertheless, SB provided additional grading information in a small number of patients. Larger studies are needed to evaluate the clinical value of selective SB omission in patients with PI-RADS 5 lesions.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-12
DOI
https://doi.org/10.3390/diagnostics16223736
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Incremental Value of Systematic Biopsy in Patients with Prostate Imaging Reporting and Data System 5 Lesions Undergoing MRI–Ultrasound Fusion Biopsy: A Single-Operator Study in a Secondary-Care Setting

Hyun Sik Yoon, Hyung Suk Kim, Jungbum Bae, Hae Won Lee
Diagnostics
Prostate Cancer Diagnosis and Treatment
article

Incremental Value of Systematic Biopsy in Patients with Prostate Imaging Reporting and Data System 5 Lesions Undergoing MRI–Ultrasound Fusion Biopsy: A Single-Operator Study in a Secondary-Care Setting

Hyun Sik Yoon, Hyung Suk Kim, Jungbum Bae, Hae Won Lee
article en

Abstract

Background/Objectives: This study aimed to evaluate the incremental value of systematic biopsy (SB) in addition to targeted biopsy (TB) and its impact on Grade Group (GG) reclassification in patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions. Methods: We retrospectively reviewed data from 32 patients with PI-RADS 5-only lesions who underwent magnetic resonance imaging–ultrasound fusion transrectal biopsy by a single operator. Based on the patient-level maximum GG, we evaluated the detection of any prostate cancer (GG ≥ 1), clinically significant prostate cancer (GG ≥ 2), and high-grade prostate cancer (GG ≥ 3). An exploratory subgroup analysis was performed according to prostate-specific antigen density (PSAD; <0.15 vs. ≥0.15 ng/mL/mL). Results: Any prostate cancer was detected in 24 patients (75.0%) using TB, with no incremental detection using SB (0.0%; 95% confidence interval [CI], 0.0–10.9). Clinically significant prostate cancer was detected in 21 patients (65.6%) using TB, with incremental detection using SB in one patient (3.1%; 95% CI, 0.1–16.2). High-grade prostate cancer was detected in 17 patients (53.1%) using TB, with incremental detection using SB in one patient (3.1%; 95% CI, 0.1–16.2). The maximum GG was higher in three patients (9.4%) when TB and SB were combined. Among the 20 patients with PSAD ≥ 0.15 ng/mL/mL, no incremental detection of clinically significant prostate cancer or high-grade prostate cancer was observed using SB (0.0%; 95% CI, 0.0–16.8). Conclusions: In this cohort of patients with PI-RADS 5 lesions, the incremental value of SB for cancer detection was limited, although the upper limit of the 95% CI for incremental detection of clinically significant prostate cancer was 16.2%. Nevertheless, SB provided additional grading information in a small number of patients. Larger studies are needed to evaluate the clinical value of selective SB omission in patients with PI-RADS 5 lesions.

DiagnosticsVol. 16(22)
Dongguk University (KR), Dongguk University Ilsan Hospital (KR)
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon